Lilly Oncology on Canvas Invites Entries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 3
Volume 15
Issue 3

Eli Lilly and Company and the National Coalition for Cancer Survivorship have issued a call for entries for the 2006 Lilly Oncology on Canvas: Expressions of a Cancer Journey International Art Competition and Exhibition.

INDIANAPOLIS—Eli Lilly and Company and the National Coalition for Cancer Survivorship have issued a call for entries for the 2006 Lilly Oncology on Canvas: Expressions of a Cancer Journey International Art Competition and Exhibition. The competition invites people diagnosed with any type of cancer, their families and friends, cancer advocates, and health care providers, as well as artists and art students, to express, through art and narrative, their own cancer journeys. Art entries will be accepted through July 30, 2006, in the following media: oil, watercolor, acrylic, pastel, photography, and other one-dimensional art. Winners of the 2004 competition can be viewed at www.lilly.com. For additional contest details and to obtain a registration form, please call 1-800-734-4131 or contact Anita Chernewski, art director, at achernewski@cprworldwideusa.com.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content